Cabio Biotech (Wuhan) Balance Sheet Health
Financial Health criteria checks 5/6
Cabio Biotech (Wuhan) has a total shareholder equity of CN¥1.5B and total debt of CN¥17.2M, which brings its debt-to-equity ratio to 1.1%. Its total assets and total liabilities are CN¥1.7B and CN¥123.2M respectively. Cabio Biotech (Wuhan)'s EBIT is CN¥98.6M making its interest coverage ratio -30.9. It has cash and short-term investments of CN¥158.6M.
Key information
1.1%
Debt to equity ratio
CN¥17.19m
Debt
| Interest coverage ratio | -30.9x |
| Cash | CN¥158.64m |
| Equity | CN¥1.54b |
| Total liabilities | CN¥123.19m |
| Total assets | CN¥1.66b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688089's short term assets (CN¥672.3M) exceed its short term liabilities (CN¥108.0M).
Long Term Liabilities: 688089's short term assets (CN¥672.3M) exceed its long term liabilities (CN¥15.2M).
Debt to Equity History and Analysis
Debt Level: 688089 has more cash than its total debt.
Reducing Debt: 688089's debt to equity ratio has increased from 0% to 1.1% over the past 5 years.
Debt Coverage: 688089's debt is well covered by operating cash flow (870%).
Interest Coverage: 688089 earns more interest than it pays, so coverage of interest payments is not a concern.